Clavispora (Candida) lusitaniae susceptibility profiles and genetic diversity in three tertiary hospitals (1998-2001) [3]

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 458-460

  Kollia, Kalomoira ^a   Arabatzis, Michael ^a   Kostoula, Olga ^a   Kostourou, Akrivi ^a,b   Velegraki, Aristea ^a   Belessiotou, Elina ^b   Lazou, Aekaterini ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; FLUCONAZOLE; FLUCYTOSINE; INTRINSIC FACTOR; ITRACONAZOLE; NYSTATIN; PYRROLE; TERBINAFINE; VORICONAZOLE;

CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDIASIS; CENTRAL VENOUS CATHETER; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; FUNGUS ISOLATION; GENE MUTATION; GENETIC VARIABILITY; HEAD AND NECK TUMOR; HEART FAILURE; HOSPITAL; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; LETTER; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUTH INFECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; SCORING SYSTEM; SEPTIC SHOCK; THRUSH; TREATMENT FAILURE; VAGINITIS;

EID: 0141457652     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00161-4     Document Type: Letter

References (10)

1. Yoon S.A., Vazquez J.A., Steffan P.E., Sobel J.D., Akins R.A. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother. 43:1999;836-845.
2. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:2002;73-85.
3. Barchiesi F., Tortorano A.M., Di Francesco L.F., Cogliati M., Scalise G., Viviani M.A. In vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J. Antimicrob. Chemother. 43:1999;295-299.
4. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. New Engl. J. Med. 331:1994;1325-1330.
5. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. 1997;NCCLS, Wayne, PA.
6. Barry A.L., Pfaller M.A., Brown A., et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:2000;3457-3459.
7. Peyron F., Favel A., Michel-Nguyen A., Gilly M., Regli P., Bolmström A. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J. Clin. Microbiol. 39:2000;339-342.
8. Bille J. When should Candida isolates be tested for susceptibility to azole antifungal agents. Eur. J. Clin. Microbiol. Infect. Dis. 38:1997;281-282.
9. Fan-Harvard P., Capano D., Smith S.M., Mangia A., Eng R.H.K. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:1991;2302-2305.
10. King D., Rhine-Chalberg J., Pfaller M.A., Moser S.A., Merz W.G. Comparison of four DNA-based methods for strain delineation of Candida lusitaniae. J. Clin. Microbiol. 33:1995;1467-1470.